ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. - Wikidata - awgldk - TriplyDB

ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.

ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.

http://www.wikidata.org/entity/Q37235591

about

ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1.Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer.HPV-negative head and neck squamous cell carcinomas: how can we use the tumor protein signature?

P2860

Q33722508-F7DCA973-7B0E-455F-AC76-1B0021A0C5E4 Q35602135-9CD4D6FB-A8FD-42BB-B4A5-27888029C9EC Q35632327-EFAB340D-79A1-4797-8B20-700E91C84656 Q37722147-3E818582-5398-4FDB-B1A8-09643687A5CC Q38267182-5EFCBFAC-5DFD-4B04-B857-495F30DC0179 Q38548142-0AAD6C87-7ADC-44BE-8452-FE53E8918D9F Q40735558-BD0E575A-B2D9-4CB2-B569-C72CADC4A51A Q41549007-5A29538D-B9EF-4BCC-9842-87766F57D896 Q41782195-667BC2CD-5078-4B93-8C52-32551AAC6015 Q51052868-9B1734C9-83EE-460E-8E27-B9ED625505EE

P2860

ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.

http://www.wikidata.org/entity/Q37235591

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.

@en

ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.

@nl

type

label

ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.

@en

ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.

@nl

prefLabel

ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.

@en

ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.

@nl

P1433

Q37235591-4BBAC2E8-6E9A-4138-981D-0074DC694016

P1476

Q37235591-EC04F9C4-ADA9-4302-9E4F-8F225C66774D

P2093

Q37235591-145909CA-DCDB-463B-B47D-3794560770ED

Q37235591-2029EB45-A685-454A-8934-C514ACE7741C

Q37235591-379E89A9-1FAA-4F5F-8D25-E4E993AF1AEB

Q37235591-6D639DCF-54A7-412E-99CA-A50E4CA5714F

Q37235591-8D4B5407-11D3-430A-AA0C-2BD84D0350F8

Q37235591-8E6B20F3-148D-4E5A-9178-D9E7B1CD129C

Q37235591-A1C5CA0C-3009-462F-BEAB-7206F42B02EE

Q37235591-B3D9BBDD-2464-43FA-96F7-A4E725B76019

Q37235591-D3299EA5-A08E-4DAC-B8BF-019F7674A3F1

P2860

Q37235591-010BB48F-250B-4C6D-A65D-63B6BCE6665E

Q37235591-0151FB7B-734B-4909-9B96-B51AB4DF84AC

Q37235591-01C0CD3F-2CB8-4129-94A4-63379CCAF63D

Q37235591-08BD3C84-722B-41D9-AF2D-44F1924D9661

Q37235591-1689F0E2-C855-48A1-AC2B-9DEF42EA4B97

Q37235591-171DC191-8AC2-4348-AF64-01D1848AB513

Q37235591-1889485B-5A33-4821-854B-CC5F7FAB5DEC

Q37235591-19B2403E-22B5-4E22-9A77-C9375F50C4CA

Q37235591-1C09B9C2-D8A3-4F42-AECD-F309EC944B84

Q37235591-41748276-5084-492A-8A3C-FF55AD6C8482

P2888

Q37235591-297CF2ED-9EB2-493C-9415-75EF49F9CA23

P304

Q37235591-27446008-EDC2-4D01-A689-B4DB53D1DB0B

P31

Q37235591-C29A0D37-A1E8-4FFC-A9F2-99B85E25D3A8

P356

Q37235591-88AC3AE9-18A3-4DFA-9705-541692A03DD5

P407

Q37235591-C5C1E095-5886-4F1F-B718-303EC083CB5A

P433

Q37235591-980DAC64-B5E3-4A35-AEFC-DF0E37A6C387

P478

Q37235591-F2C3EECA-2024-46D4-BBCD-0626824ECE48

P50

Q37235591-7FD2FBF2-4021-40A3-AF4F-51A6C87E5394

Q37235591-DAEAAC38-43D5-4DBB-B7EB-2E6882AF3EF9

P577

Q37235591-682F6296-A94D-4AC0-9679-AB6E9815F048

P5875

Q37235591-A207FB6C-A29F-4E85-A470-104BF35A2FF7

P6179

Q37235591-1238F886-E451-4D5C-90D1-797EB09C4F00

P698

Q37235591-6AF72454-2C6C-478C-B01A-BB4561819D22

P921

Q37235591-8261BF66-DD99-415C-935C-4AAE329FB749

Q37235591-F809C848-C70D-4B80-9A84-9A6A1A030841

P932

Q37235591-3928638E-9970-4C5E-801D-AEF29E79D952

P356

P1433

British Journal of Cancer

P1476

ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.

@en

P2093

A Vaezi

http://www.w3.org/2001/XMLSchema#string

D N Hayes

http://www.w3.org/2001/XMLSchema#string

E Mendez

http://www.w3.org/2001/XMLSchema#string

J E Bauman

http://www.w3.org/2001/XMLSchema#string

M C Austin

http://www.w3.org/2001/XMLSchema#string

R G Martins

http://www.w3.org/2001/XMLSchema#string

R Schmidt

http://www.w3.org/2001/XMLSchema#string

S Sampath

http://www.w3.org/2001/XMLSchema#string

X Chai

http://www.w3.org/2001/XMLSchema#string

P2860

Human papillomavirus and survival of patients with oropharyngeal cancer.

Cancer statistics, 2010

Cancer statistics, 2012

A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis

ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

Combination of taxanes with radiation: preclinical studies.

Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology

P2888

P304

2096-2105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2013.576

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Upendra Parvathaneni

P577

2013-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257071392

http://www.w3.org/2001/XMLSchema#string

P6179

1009168245

http://www.w3.org/2001/XMLSchema#string

P698

24064970

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3798971

http://www.w3.org/2001/XMLSchema#string